Strategic partnerships Leverage the recent €108M licensing deal in Asia with LG Chem Life Science to explore co-development, regional manufacturing, or exclusive distribution arrangements in other regions, highlighting PDC*line’s off-the-shelf cancer vaccine platform as a scalable collaboration opportunity.

Clinical expansion Target partnerships with oncology-focused pharma and contract research organizations to support the advancing Phase II randomized lung cancer trial (PDC*lung) and the Phase Ib colorectal cancer neoantigen program (PDC*neo), offering access to shared clinical development resources and biomarker strategies.

Immunotherapy portfolio Position PDC*line’s cell-based immunotherapy platform as a complementary or plug-in option to existing PD-1/PD-L1 and CTLA-4 programs, enabling biotech and pharma companies to augment their immuno-oncology pipelines with a novel off-the-shelf vaccine approach.

Geographic potential Capitalize on biregional partnerships in Europe and Asia where funding and regional clusters (Walloon region, BioWin) have supported PDC*line; propose regional commercialization rights, co-marketing, and clinical trial site access to accelerate market entry.

Funding readiness Highlight the company’s strong funding trajectory, including €61M in equity and non-dilutive funding and prior Series B financing, to engage investors and strategic customers with a narrative of proven financial backing and rapid clinical progression.